ClinicalTrials.gg

Program

abefolastat tesaroxetan CU-64

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Clarity Pharmaceuticals.

Furthest: phase 3, since Sep 21, 20235 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clarity Pharmaceuticals53 open or runningphase 3since Sep 21, 2023Apr 7, 2021Dec 31, 2026phase 3 · NCT06970847

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2021First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04839367 · 30 enrolled · Australia
  2. Apr 15, 2021Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT04868604 · 54 planned · United States
  3. Feb 2, 2022Phase 2 study in Biochemical Recurrence of Malignant Neoplasm of ProstateNCT05249127 · 52 enrolled · United States
  4. Sep 21, 2023Phase 3 study in Prostatic NeoplasmsNCT06056830 · 383 planned · United States, Australia, Puerto Rico
  5. Apr 29, 2025Phase 3 study in Prostatic NeoplasmsNCT06970847 · 220 enrolled · United States, Australia

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Prostatic NeoplasmsNCT06970847

TargetBeta

FOLH1 →read by rule
“A radioconjugate composed of abefolastat tesaroxetan, two human prostate-specific membrane antigen (PSMA) binding motifs ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06970847Prostatic Neoplasms · United States, Australia3Active, not recruitingDec 31, 2026220
NCT06056830Prostatic Neoplasms · United States, Australia, Puerto Rico3RecruitingSep 2026383
NCT05249127Biochemical Recurrence of Malignant Neoplasm of Prostate · United States2CompletedAug 8, 202352
NCT04868604Prostatic Neoplasms, Castration-Resistant · United States2RecruitingSep 202654
NCT04839367Prostatic Neoplasms · Australia1CompletedOct 19, 202230

How it is read

Names in the registry

  • “64Cu-SAR-bisPSMA”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.